Your browser doesn't support javascript.
loading
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment.
Peter, Madonna R; Bilenky, Misha; Isserlin, Ruth; Bader, Gary D; Shen, Shu Yi; De Carvalho, Daniel D; Hansen, Aaron R; Hu, Pingzhao; Fleshner, Neil E; Joshua, Anthony M; Hirst, Martin; Bapat, Bharati.
Afiliación
  • Peter MR; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, M5G 1X5, Canada.
  • Bilenky M; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
  • Isserlin R; Canada's Michael Smith Genome Science Centre, BC Cancer Agency, Vancouver, BC, V5Z 4S6, Canada.
  • Bader GD; Donnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, ON, M5S 3E1, Canada.
  • Shen SY; Donnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, ON, M5S 3E1, Canada.
  • De Carvalho DD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2C1, Canada.
  • Hansen AR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2C1, Canada.
  • Hu P; Department of Medical Biophysics, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Fleshner NE; Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C1, Canada.
  • Joshua AM; Department of Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, MB, R3E 3N4, Canada.
  • Hirst M; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, M5G 2C1, Canada.
  • Bapat B; Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C1, Canada.
Epigenomics ; 12(15): 1317-1332, 2020 08.
Article en En | MEDLINE | ID: mdl-32867540
ABSTRACT

Aim:

We examined methylation changes in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC) during treatment. Patients &

methods:

Genome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting therapy was performed.

Results:

Alterations in methylation states of genes previously implicated in prostate cancer progression were observed and patients that maintained methylation changes throughout therapy tended to have a longer time to clinical progression. Importantly, we also report that markers associated with a highly aggressive form of the disease, neuroendocrine-CRPC, were associated with a faster time to clinical progression.

Conclusion:

Our findings highlight the potential of monitoring the cfDNA methylome during therapy in mCRPC, which may serve as predictive markers of response to androgen-targeting agents.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Epigenoma Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Epigenomics Año: 2020 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Epigenoma Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Epigenomics Año: 2020 Tipo del documento: Article País de afiliación: Canadá